Literature DB >> 28856946

Spontaneous HIT syndrome post-knee replacement surgery with delayed recovery of thrombocytopenia: a case report and literature review.

Dilli Ram Poudel1, Sushil Ghimire1, Rashmi Dhital1, Daniel A Forman1, Theodore E Warkentin2.   

Abstract

Recently published reports have established a heparin-induced thrombocytopenia (HIT)-mimicking thromboembolic disorder without proximate heparin exposure, called spontaneous HIT syndrome. Although the pathophysiology remains unclear, anti-platelet factor 4 (PF4)/heparin antibodies possibly triggered by exposure to knee cartilage glycosaminoglycans or other non-heparin polyanions found on bacterial surfaces and nucleic acids have been postulated. We present a 53-year-old female receiving antithrombotic prophylaxis with aspirin following right total knee replacement surgery (without perioperative or any previous lifetime heparin exposure) who acutely presented with high-risk pulmonary embolism (PE) and right great saphenous vein thrombophlebitis on postoperative day (POD) 14; her platelet count at presentation was 13 × 109/L. Prior to diagnostic consideration of spontaneous HIT syndrome, the patient briefly received unfractionated heparin (UFH) and one dose of enoxaparin. The patient's serum tested strongly positive for anti-PF4/heparin antibodies by two different PF4-dependent enzyme-linked immunosorbent assays (ELISAs) and by serotonin release assay (SRA). Failure of fondaparinux anticoagulation (persisting HIT-associated disseminated intravascular coagulation) prompted switching to argatroban. Severe thrombocytopenia persisted (platelet count nadir, 12 × 109/L, on POD21), and 9 days after starting argatroban symptomatic right leg deep-vein thrombosis (DVT) occurred, prompting switch to rivaroxaban. Thereafter, her course was uneventful, although platelet count recovery was prolonged, reaching 99 × 109/L by POD45 and 199 × 109/L by POD79. The patient's serum elicited strong serotonin release in the absence of heparin (seen even with 1/32 serum dilution) that was enhanced by pharmacological concentrations of UFH (0.1 and 0.3 IU/mL) and fondaparinux (0.1-1.2 μg/mL, i.e., in vitro fondaparinux "cross-reactivity"). Ultimately, platelet count recovery was associated with seroreversion to a negative SRA (documented at POD151). Our literature review identified joint replacement surgery, specifically knee replacement, to be a relatively common trigger of spontaneous HIT syndrome. Further, including our patient case, 5 of 7 patients with spontaneous HIT syndrome post-orthopedic surgery who received treatment with argatroban developed new and/or progressive lower-limb DVT or recurrent PE despite anticoagulation with this parenteral direct thrombin inhibitor, suggesting that this patient population is at high risk of breakthrough thrombotic events despite treatment with this HIT treatment-approved anticoagulant. Our case also illustrates successful outcome with rivaroxaban for treatment of spontaneous HIT syndrome, consistent with emerging literature supporting safety and efficacy of direct oral anticoagulant therapy for treatment of acute HIT.

Entities:  

Keywords:  Argatroban; fondaparinux; knee replacement; rivaroxaban; spontaneous HIT syndrome

Mesh:

Substances:

Year:  2017        PMID: 28856946     DOI: 10.1080/09537104.2017.1366973

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  18 in total

Review 1.  Anticoagulating patients with high-risk acquired thrombophilias.

Authors:  Leslie Skeith
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Induction of anti-PF4/heparin antibodies after arthroplasty for rheumatic diseases.

Authors:  Kiyoshi Migita; Tomoyuki Asano; Shuzo Sato; Satoru Motokawa
Journal:  Fukushima J Med Sci       Date:  2018-04-07

3.  Use of intravenous immunoglobulin G to treat spontaneous heparin-induced thrombocytopenia.

Authors:  Mehraboon Irani; Eric Siegal; Abhay Jella; Richard Aster; Anand Padmanabhan
Journal:  Transfusion       Date:  2018-12-17       Impact factor: 3.157

4.  Spontaneous Heparin-Induced Thrombocytopenia Presenting as Acute Ischemic Stroke.

Authors:  Christopher J Becker; Amelia L Heston; Joseph F Carrera
Journal:  Neurol Clin Pract       Date:  2021-12

5.  Delayed-Onset Heparin-Induced Thrombocytopenia With Cerebral Venous Sinus Thrombosis Following Total Knee Arthroplasty: Case Report.

Authors:  Megan M J Bauman; Ryan M Naylor; Ashley R Santilli; Eelco F Wijdicks
Journal:  Neurohospitalist       Date:  2021-08-26

6.  Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection.

Authors:  Eileen Shiuan; Deva Sharma; E Wesley Ely; Nikil Moodabagil; Benjamin F Tillman
Journal:  J Thromb Thrombolysis       Date:  2022-06-28       Impact factor: 5.221

Review 7.  Heparin-Induced Thrombocytopenia: A Focus on Thrombosis.

Authors:  Gowthami M Arepally; Anand Padmanabhan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-03       Impact factor: 8.311

8.  Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination.

Authors:  Jonathan Douxfils; Julien Favresse; Jean-Michel Dogné; Thomas Lecompte; Sophie Susen; Charlotte Cordonnier; Aurélien Lebreton; Robert Gosselin; Pierre Sié; Gilles Pernod; Yves Gruel; Philippe Nguyen; Caroline Vayne; François Mullier
Journal:  Thromb Res       Date:  2021-05-15       Impact factor: 3.944

9.  A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2.

Authors:  Anne Louise Tølbøll Sørensen; Magalie Rolland; Jacob Hartmann; Zitta Barrella Harboe; Casper Roed; Tomas Ø Jensen; Lilian Kolte; Daniel El Fassi; Jens Hillingsø; Aneta Radziwon-Balicka; Robert Sebastian Soyka; Klaus Hansen; Nikolai Kirkby; Jens P Goetze; Mikkel Gybel-Brask; Eva Birgitte Leinøe; Anne-Mette Hvas; Peter Kampmann; Jakob Stensballe
Journal:  Blood Adv       Date:  2021-06-22

10.  A practical approach to evaluating postoperative thrombocytopenia.

Authors:  Leslie Skeith; Lisa Baumann Kreuziger; Mark A Crowther; Theodore E Warkentin
Journal:  Blood Adv       Date:  2020-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.